von Tobias Borgers | Aug 24, 2019 | Glaxo
Issued: London UK GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive headline results from the pivotal DREAMM-2 open-label, randomised study of two doses of belantamab mafodotin (GSK2857916). The 196 patients in the trial had relapsed multiple myeloma, were...
von Tobias Borgers | Aug 24, 2019 | Boehringer
Overview: Parkinson’s disease is one of the most prevalent neurodegenerative disorders, which progresses with age because of damaged dopaminergic cells in the brain. Bradykinesia, rigidity, postural instability, and tremors are the symptoms of the Parkinson’s disease....
von Tobias Borgers | Aug 23, 2019 | Kunden
Kompaktes Design 22.08.2019 Mit dem neuen Elematic 2001 bietet Bosch Packaging Technology eine Lösung für die Endverpackung. Der Sammelpacker bietet ein kompaktes Maschinendesign und benötigt so im Vergleich zum Vorgängermodell 25 % weniger Platz. Entscheider-Facts 25...
von Tobias Borgers | Aug 23, 2019 | MSD
Pressemitteilung Finale Analyse der zulassungsrelevanten Phase-III-Studie KEYNOTE-048: Verbessertes Gesamtüberleben für Patienten unter Pembrolizumab (KEYTRUDA®) in der Erstlinientherapie des rezidivierenden oder metastasierenden Plattenepithelkarzinoms der...
von Tobias Borgers | Aug 23, 2019 | Boehringer
The Global Pancreatic Beta-Cell Protection Market report presents an overview of objectives study and definition of Pancreatic Beta-Cell Protection market. This new market research report forecasts on Pancreatic Beta-Cell Protection Market providing complete market...
von Tobias Borgers | Aug 23, 2019 | Glaxo
Issued: London, UK ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive headline results from its global phase III ATLAS-2M study of the investigational, long-acting,...
